Anavex Life Sciences Corp (AVXL)

[falconer66a]

The blarcamesine safety factor.

Yes, plausible reasons why Missling and company have been quiet regarding a big Parkinson's disease dementia study, an anticipated Phase 3 study. Data from the very successful Phase 2 study, coupled with the ensuing big Phase 3 Alzheimer's study might seal the deal without a Parkinson's dementia disease Phase 3.

Unmentioned in all of this intelligent speculation is the additional factor of blarcamesine's utter safety. No adverse events (side effects) in any murine (lab rodent) or human trials --- VERY rare in drugs working inside the central nervous system. One of the reasons for long, big Phase 3 trials is to prove not only that the drugs being tested are efficacious (actually work), but, at the same time don't induce side effects that cause other severe, complicating outcomes.

The demonstrated blarcamesine safety factor, especially on the long Phase 3 Alzheimer's study, will be a big factor allowing approval without a Phase 3 for the Parkinson's cohort.